
Pietro Invernizzi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8742349/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The application of artificial intelligence in hepatology: A systematic review. Digestive and Liver Disease, 2022, 54, 299-308.	0.9	13
2	The proteaseâ€inhibitor SerpinB3 as a critical modulator of the stemâ€like subset in human cholangiocarcinoma. Liver International, 2022, 42, 233-248.	3.9	15
3	Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CTâ€P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): AÂmulticenter cohort study. Clinical and Translational Science, 2022, 15, 172-181.	3.1	18
4	E. coli and the etiology of human PBC: Antimitochondrial antibodies and spreading determinants. Hepatology, 2022, 75, 266-279.	7.3	18
5	Somatostatin analogs in patients with Zollinger Ellison syndrome (ZES): an observational study. Endocrine, 2022, 75, 942-948.	2.3	5
6	The mode of dexamethasone decoration influences avidin-nucleic-acid-nano-assembly organ biodistribution and in vivo drug persistence. Nanomedicine: Nanotechnology, Biology, and Medicine, 2022, 40, 102497.	3.3	4
7	Effects of immunosuppressive drugs on COVIDâ€19 severity in patients with autoimmune hepatitis. Liver International, 2022, 42, 607-614.	3.9	26
8	Machine learning in primary biliary cholangitis: A novel approach for risk stratification. Liver International, 2022, 42, 615-627.	3.9	7
9	An update on novel pharmacological agents for primary sclerosing cholangitis. Expert Opinion on Therapeutic Targets, 2022, 26, 69-77.	3.4	5
10	Recognition and inhibition of SARS-CoV-2 by humoral innate immunity pattern recognition molecules. Nature Immunology, 2022, 23, 275-286.	14.5	95
11	Intratumor Microbiome in Neuroendocrine Neoplasms: A New Partner of Tumor Microenvironment? A Pilot Study. Cells, 2022, 11, 692.	4.1	8
12	Rectal neuroendocrine tumors: Current advances in management, treatment, and surveillance. World Journal of Gastroenterology, 2022, 28, 1123-1138.	3.3	16
13	X marks the spot in autoimmunity. Expert Review of Clinical Immunology, 2022, 18, 429-437.	3.0	0
14	Primary biliary cholangitis: perception and expectation of illness. Digestive and Liver Disease, 2022, 54, 1230-1233.	0.9	1
15	Hepatitis C virus infection and diabetes: a complex bidirectional relationship. Diabetes Research and Clinical Practice, 2022, , 109870.	2.8	3
16	Impact of the new definition of metabolic dysfunction–associated fatty liver disease on detection of significant liver fibrosis in US adolescents. Hepatology Communications, 2022, 6, 2070-2078.	4.3	12
17	The Role of Epigenetics in Primary Biliary Cholangitis. International Journal of Molecular Sciences, 2022, 23, 4873.	4.1	11
18	Duodenal Gastric Metaplasia and Duodenal Neuroendocrine Neoplasms: More Than a Simple Coincidence?. Journal of Clinical Medicine, 2022, 11, 2658.	2.4	3

#	Article	IF	CITATIONS
19	Systematic review—pancreatic involvement in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2022, 55, 1478-1491.	3.7	18
20	Reply to: Hultström et al., Genetic determinants of mannose-binding lectin activity predispose to thromboembolic complications in critical COVID-19. Mannose-binding lectin genetics in COVID-19. Nature Immunology, 2022, 23, 865-867.	14.5	4
21	The Role of Macrophages in Liver Fibrosis: New Therapeutic Opportunities. International Journal of Molecular Sciences, 2022, 23, 6649.	4.1	18
22	Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis. Journal of Hepatology, 2022, 77, 1545-1553.	3.7	33
23	Clinical treatment of cholangiocarcinoma: an updated comprehensive review. Annals of Hepatology, 2022, 27, 100737.	1.5	43
24	Endoscopic techniques for diagnosis and treatment of gastro-entero-pancreatic neuroendocrine neoplasms: Where we are. World Journal of Gastroenterology, 2022, 28, 3258-3273.	3.3	13
25	Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis. Clinical Gastroenterology and Hepatology, 2021, 19, 1688-1697.e14.	4.4	30
26	Second primary neoplasms in patients with lung and gastroenteropancreatic neuroendocrine neoplasms: Data from a retrospective multi-centric study. Digestive and Liver Disease, 2021, 53, 367-374.	0.9	12
27	Reply to: "A spotlight on natural killer cells in primary biliary cholangitis― Journal of Hepatology, 2021, 74, 255-256.	3.7	0
28	Identifying Racial Disparities in Primary Biliary Cholangitis Patients: A Step Toward Achieving Equitable Outcomes Among All. Digestive Diseases and Sciences, 2021, 66, 1386-1387.	2.3	0
29	DCLK1, a Putative Stem Cell Marker in Human Cholangiocarcinoma. Hepatology, 2021, 73, 144-159.	7.3	29
30	Takayasu arteritis and primary sclerosing cholangitis: A casual association or different phenotypes of the same disease?. Journal of Translational Autoimmunity, 2021, 4, 100124.	4.0	0
31	Elastography in Autoimmune Liver Diseases. , 2021, , 91-103.		0
32	Antiâ€gp210 and other antiâ€nuclear pore complex autoantibodies in primary biliary cholangitis: What we know and what we should know. Liver International, 2021, 41, 432-435.	3.9	4
33	The seat of life. What a lesson from the stigmatized saints. Liver International, 2021, 41, 1675-1676.	3.9	2
34	Risk of preoperative understaging of duodenal neuroendocrine neoplasms: a plea for caution in the treatment strategy. Journal of Endocrinological Investigation, 2021, 44, 2227-2234.	3.3	13
35	Immune-Mediated Drug-Induced Liver Injury: Immunogenetics and Experimental Models. International Journal of Molecular Sciences, 2021, 22, 4557.	4.1	34
36	Old and novel prognostic biomarkers in primary biliary cholangitis. Expert Opinion on Orphan Drugs, 2021, 9, 123-131.	0.8	0

#	Article	IF	CITATIONS
37	Case Report: Hypomorphic Function and Somatic Reversion in DOCK8 Deficiency in One Patient With Two Novel Variants and Sclerosing Cholangitis. Frontiers in Immunology, 2021, 12, 673487.	4.8	5
38	Real-world experience with obeticholic acid in patients with primary biliary cholangitis. JHEP Reports, 2021, 3, 100248.	4.9	33
39	Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort. Digestive and Liver Disease, 2021, 53, 1603-1609.	0.9	2
40	Accuracy of Transient Elastography in Assessing Fibrosis at Diagnosis in NaÃ⁻ve Patients With Primary Biliary Cholangitis: A Dual Cutâ€Off Approach. Hepatology, 2021, 74, 1496-1508.	7.3	28
41	Outcome of COVIDâ€19 in Patients With Autoimmune Hepatitis: An International Multicenter Study. Hepatology, 2021, 73, 2099-2109.	7.3	56
42	X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis. Gastroenterology, 2021, 160, 2483-2495.e26.	1.3	27
43	Acute mesenteric ischemia and small bowel imaging findings in COVID-19: A comprehensive review of the literature. World Journal of Gastrointestinal Surgery, 2021, 13, 702-716.	1.5	13
44	An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs. Journal of Hepatology, 2021, 75, 572-581.	3.7	62
45	The genetic architecture of primary biliary cholangitis. European Journal of Medical Genetics, 2021, 64, 104292.	1.3	18
46	Gastrinoma and Zollinger Ellison syndrome: A roadmap for the management between new and old therapies. World Journal of Gastroenterology, 2021, 27, 5890-5907.	3.3	26
47	Impact of COVID-19 on inflammatory bowel disease practice and perspectives for the future. World Journal of Gastroenterology, 2021, 27, 5520-5535.	3.3	10
48	Quality of life in patients with primary biliary cholangitis: A cross-geographical comparison. Journal of Translational Autoimmunity, 2021, 4, 100081.	4.0	7
49	Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficultâ€ŧoâ€ŧreat primary biliary cholangitis. Alimentary Pharmacology and Therapeutics, 2021, 53, 1138-1146.	3.7	37
50	PTU-46â€Safety and efficacy of fully covered metallic stent placement for patients with primary sclerosing cholangitis. , 2021, , .		0
51	MEDTEC Students against Coronavirus: Investigating the Role of Hemostatic Genes in the Predisposition to COVID-19 Severity. Journal of Personalized Medicine, 2021, 11, 1166.	2.5	7
52	Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature. Immunotherapy, 2021, , .	2.0	3
53	Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis. Clinical Gastroenterology and Hepatology, 2020, 18, 684-692.e6.	4.4	17
54	Modulation of the Tryptophan Hydroxylase 1/Monoamine Oxidaseâ€A/5â€Hydroxytryptamine/5â€Hydroxytryptamine Receptor 2A/2B/2C Axis Regulates Biliary Proliferation and Liver Fibrosis During Cholestasis. Hepatology, 2020, 71, 990-1008.	7.3	23

#	Article	IF	CITATIONS
55	Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies. Annals of Hepatology, 2020, 19, 5-16.	1.5	13
56	Understanding short bowel syndrome: Current status and future perspectives. Digestive and Liver Disease, 2020, 52, 253-261.	0.9	82
57	Letter to the Editor: Might Denosumab Fit in Primary Biliary Cholangitis Treatment?. Hepatology, 2020, 72, 359-360.	7.3	3
58	Individualizing Care. Surgical Oncology Clinics of North America, 2020, 29, 87-103.	1.5	0
59	Hepatic focal nodular hyperplasia after pediatric hematopoietic stem cell transplantation: The impact of hormonal replacement therapy and iron overload. Pediatric Blood and Cancer, 2020, 67, e28137.	1.5	9
60	Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study. Digestive and Liver Disease, 2020, 52, 190-198.	0.9	12
61	Response and relapse rates after treatment with longâ€acting somatostatin analogs in multifocal or recurrent typeâ€1 gastric carcinoids: A systematic review and metaâ€analysis. United European Gastroenterology Journal, 2020, 8, 140-147.	3.8	17
62	Cost of illness of Primary Biliary Cholangitis - a population-based study. Digestive and Liver Disease, 2020, 53, 1167-1170.	0.9	3
63	Gastro-entero-pancreatic neuroendocrine neoplasia: The rules for non-operative management. Surgical Oncology, 2020, 35, 141-148.	1.6	14
64	Primary biliary cholangitis: a multifaceted pathogenesis with potential therapeutic targets. Journal of Hepatology, 2020, 73, 965-966.	3.7	14
65	2020 international consensus on ANCA testing beyond systemic vasculitis. Autoimmunity Reviews, 2020, 19, 102618.	5.8	79
66	Coronavirus Disease 2019 in Autoimmune Hepatitis: A Lesson From Immunosuppressed Patients. Hepatology Communications, 2020, 4, 1257-1262.	4.3	55
67	Primary biliary cholangitis management: controversies, perspectives and daily practice implications from an expert panel. Liver International, 2020, 40, 2590-2601.	3.9	15
68	COVID-19 in Patients With Inflammatory Bowel Disease: A Single-center Observational Study in Northern Italy. Inflammatory Bowel Diseases, 2020, 26, e138-e139.	1.9	8
69	Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) â‰열 cm: Study Protocol for a Prospective Observational Study. Frontiers in Medicine, 2020, 7, 598438.	2.6	33
70	Primary Sclerosing Cholangitis: Burden of Disease and Mortality Using Data from the National Rare Diseases Registry in Italy. International Journal of Environmental Research and Public Health, 2020, 17, 3095.	2.6	17
71	Endoscopic Findings in Patients Infected With 2019 Novel Coronavirus in Lombardy, Italy. Clinical Gastroenterology and Hepatology, 2020, 18, 2375-2377.	4.4	35
72	Primary Biliary Cholangitis and Bile Acid Farnesoid X Receptor Agonists. Diseases (Basel, Switzerland), 2020, 8, 20.	2.5	14

#	Article	IF	CITATIONS
73	Genomewide Association Study of Severe Covid-19 with Respiratory Failure. New England Journal of Medicine, 2020, 383, 1522-1534.	27.0	1,548
74	Glycomic analysis of antibody indicates distinctive glycosylation profile in patients with autoimmune cholangitis. Journal of Autoimmunity, 2020, 113, 102503.	6.5	5
75	High rates of 30-day mortality in patients with cirrhosis and COVID-19. Journal of Hepatology, 2020, 73, 1063-1071.	3.7	279
76	Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitis. Liver International, 2020, 40, 1121-1129.	3.9	15
77	Multifaceted Aspects of Metabolic Plasticity in Human Cholangiocarcinoma: An Overview of Current Perspectives. Cells, 2020, 9, 596.	4.1	13
78	New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma. Cells, 2020, 9, 688.	4.1	58
79	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 557-588.	17.8	1,155
80	Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. American Journal of Gastroenterology, 2020, 115, 1066-1074.	0.4	74
81	Perception of illness in Italian patients with Primary Biliary Cholangitis referred to tertiary care units. Digestive and Liver Disease, 2020, 52, e6.	0.9	0
82	Comment on "Early Prognostic Utility of Gp210 Antibody-Positive Rate in Primary Biliary Cholangitis: A Meta-Analysis― Disease Markers, 2020, 2020, 1-2.	1.3	1
83	Serum gamma-glutamyltransferase is a prognostic biomarker in primary biliary cholangitis and improves risk stratification based on alkaline phosphatase. Digestive and Liver Disease, 2020, 52, e4-e5.	0.9	0
84	Additive beneficial effects of Fibrates combined with Obeticholic acid in the treatment of patients with Primary Biliary Cholangitis and inadequate response to second-line therapy: data from the Italian PBC Study Group. Digestive and Liver Disease, 2020, 52, e32.	0.9	2
85	Immune system and cholangiocytes: A puzzling affair in primary biliary cholangitis. Journal of Leukocyte Biology, 2020, 108, 659-671.	3.3	22
86	Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis. Liver International, 2020, 40, 1408-1414.	3.9	22
87	New Therapeutic Targets in Autoimmune Cholangiopathies. Frontiers in Medicine, 2020, 7, 117.	2.6	22
88	Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohortâ [°] †. Journal of Hepatology, 2020, 73, 505-515.	3.7	279
89	Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis. Gut, 2020, 69, 1502-1509.	12.1	28
90	Management of patients with autoimmune liver disease during COVID-19 pandemic. Journal of Hepatology, 2020, 73, 453-455.	3.7	51

6

#	Article	IF	CITATIONS
91	Open challenges in the management of autoimmune hepatitis. Minerva Gastroenterology, 2020, , .	0.5	2
92	Acute carnosine and Î ² -alanine supplementation increase the compensated part of the ventilation versus work rate relationship during a ramp incremental cycle test in physically active men. Journal of Sports Medicine and Physical Fitness, 2020, 61, 37-43.	0.7	2
93	Simplified care-pathway selection for nonspecialist practice. European Journal of Gastroenterology and Hepatology, 2020, Publish Ahead of Print, .	1.6	2
94	Genetics of Autoimmune Liver Diseases. , 2020, , 69-85.		3
95	Combined ursodeoxycholic acid/secretin treatment reduces biliary senescence and liver fibrosis in a murine model of late stage primary biliary cholangitis. FASEB Journal, 2020, 34, 1-1.	0.5	0
96	Risk stratification in primary sclerosing cholangitis. Minerva Gastroenterology, 2020, , .	0.5	2
97	FRI-016-Validation of the PREsTo machine learning algorithm for the prediction of disease progression in patients with primary sclerosing cholangitis. Journal of Hepatology, 2019, 70, e390-e391.	3.7	2
98	Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development. Journal of Hepatology, 2019, 71, 1216-1228.	3.7	388
99	A National Hospitalâ€Based Study of Hospitalized Patients With Primary Biliary Cholangitis. Hepatology Communications, 2019, 3, 1250-1257.	4.3	11
100	Antitumor Activity of a Novel Fibroblast Growth Factor Receptor Inhibitor for Intrahepatic Cholangiocarcinoma. American Journal of Pathology, 2019, 189, 2090-2101.	3.8	17
101	Secretin/secretin receptor signaling mediates biliary damage and liver fibrosis in earlyâ€stage primary biliary cholangitis. FASEB Journal, 2019, 33, 10269-10279.	0.5	32
102	FRI-021-Comparing the predictive performance of the Mayo risk score and the GLOBE score in a large cohort of patients with primary biliary cholangitis. Journal of Hepatology, 2019, 70, e392-e393.	3.7	0
103	Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response. Alimentary Pharmacology and Therapeutics, 2019, 50, 1127-1136.	3.7	66
104	Mo1470 – Secretin/Secretin Receptor Signaling Modulates Biliary Immunobiology and Subsequent T Cell Migration in Early Stage Primary Biliary Cholangitis (PBC). Gastroenterology, 2019, 156, S-1318.	1.3	1
105	THU-010-Shedding light on the X chromosome contribution to the genetic architecture of primary biliary cholangitis. Journal of Hepatology, 2019, 70, e165.	3.7	0
106	FRI-008-Incidence, prevalence and mortality of primary sclerosing cholangitis in Italy: A population-based study. Journal of Hepatology, 2019, 70, e386.	3.7	0
107	Downregulation of hepatic stem cell factor by Vivo-Morpholino treatment inhibits mast cell migration and decreases biliary damage/senescence and liver fibrosis in Mdr2â^'/â²' mice. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 165557.	3.8	25
108	The challenges of primary biliary cholangitis: What is new and what needs to be done. Journal of Autoimmunity, 2019, 105, 102328.	6.5	86

#	Article	IF	CITATIONS
109	THU-128-Renal safety in 3,264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study. Journal of Hepatology, 2019, 70, e215-e216.	3.7	0
110	Editorial: liver transplantation for primary biliary cholangitis–the need for timely and more effective treatments. Alimentary Pharmacology and Therapeutics, 2019, 49, 472-473.	3.7	4
111	Knockout of α-calcitonin gene-related peptide attenuates cholestatic liver injury by differentially regulating cellular senescence of hepatic stellate cells and cholangiocytes. Laboratory Investigation, 2019, 99, 764-776.	3.7	14
112	Multi-Teaching Styles Approach and Active Reflection: Effectiveness in Improving Fitness Level, Motor Competence, Enjoyment, Amount of Physical Activity, and Effects on the Perception of Physical Education Lessons in Primary School Children. Sustainability, 2019, 11, 405.	3.2	49
113	GS-02-Efficacy of GKT831 in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid: Interim efficacy results of a phase 2 clinical trial. Journal of Hepatology, 2019, 70, e1-e2.	3.7	18
114	Autoantibodies in patients with interleukin 12 receptor beta 1 deficiency. Journal of Digestive Diseases, 2019, 20, 363-370.	1.5	6
115	Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success. Breast Cancer Research and Treatment, 2019, 176, 483-494.	2.5	28
116	Precision medicine in primary biliary cholangitis. Journal of Digestive Diseases, 2019, 20, 338-345.	1.5	9
117	CXCR7 contributes to the aggressive phenotype of cholangiocarcinoma cells. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 2246-2256.	3.8	14
118	Novel biomarkers for primary biliary cholangitis to improve diagnosis and understand underlying regulatory mechanisms. Liver International, 2019, 39, 2124-2135.	3.9	10
119	FRI-046-Raising awareness and messaging risk in patients with primary biliary cholangitis: The rapid Global PBC Screening Test. Journal of Hepatology, 2019, 70, e404.	3.7	1
120	FRI-011-Ductular reaction, intermediate hepatocites and fibrosis extension correlate with prediction of treatment failure to ursodeoxycholic acid in primary biliary cholangitis. Journal of Hepatology, 2019, 70, e387-e388.	3.7	0
121	Pinealectomy or light exposure exacerbates biliary damage and liver fibrosis in cholestatic rats through decreased melatonin synthesis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 1525-1539.	3.8	18
122	Dexamethasone Conjugation to Biodegradable Avidin-Nucleic-Acid-Nano-Assemblies Promotes Selective Liver Targeting and Improves Therapeutic Efficacy in an Autoimmune Hepatitis Murine Model. ACS Nano, 2019, 13, 4410-4423.	14.6	47
123	Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. Clinical Gastroenterology and Hepatology, 2019, 17, 2076-2084.e2.	4.4	54
124	Experimental models to unravel the molecular pathogenesis, cell of origin and stem cell properties of cholangiocarcinoma. Liver International, 2019, 39, 79-97.	3.9	25
125	Iron Metabolism in Liver Cancer Stem Cells. Frontiers in Oncology, 2019, 9, 149.	2.8	17
126	Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. Journal of Hepatology, 2019, 71, 357-365.	3.7	148

#	Article	IF	CITATIONS
127	Amelioration of Ductular Reaction by Stem Cell Derived Extracellular Vesicles in MDR2 Knockout Mice via Lethalâ€7 microRNA. Hepatology, 2019, 69, 2562-2578.	7.3	32
128	Ductular reaction, intermediate hepatocytes and fibrosis extension correlate with prediction of treatment failure to ursodeoxycholic acid in primary biliary cholangitis. Digestive and Liver Disease, 2019, 51, e1.	0.9	0
129	Better end points needed in primary sclerosing cholangitis trials. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 143-144.	17.8	5
130	The changing face of chronic autoimmune atrophic gastritis: an updated comprehensive perspective. Autoimmunity Reviews, 2019, 18, 215-222.	5.8	94
131	Free episomal and integrated HBV DNA in HBsAg-negative patients with intrahepatic cholangiocarcinoma. Oncotarget, 2019, 10, 3931-3938.	1.8	6
132	Clinical and prognostic implications of acute onset of Autoimmune Hepatitis: An Italian multicentre study. Digestive and Liver Disease, 2018, 50, 698-702.	0.9	21
133	Comprehensive review of autoantibodies in patients with hyper-IgM syndrome. Cellular and Molecular Immunology, 2018, 15, 610-617.	10.5	12
134	Geoepidemiology of Primary Biliary Cholangitis: Lessons from Switzerland. Clinical Reviews in Allergy and Immunology, 2018, 54, 295-306.	6.5	12
135	Nlâ€0801, an antiâ€chemokine (Câ€Xâ€C motif) ligand 10 antibody, in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid. Hepatology Communications, 2018, 2, 492-503.	4.3	35
136	Blocking H1/H2 histamine receptors inhibits damage/fibrosis in Mdr2–/– mice and human cholangiocarcinoma tumorigenesis. Hepatology, 2018, 68, 1042-1056.	7.3	50
137	Pre-treatment risk stratification in primary biliary cholangitis: A predictive model to guide first-line combination therapy. Digestive and Liver Disease, 2018, 50, 21-22.	0.9	2
138	Durable response in the markers of cholestasis through 36 months of open-label extension with obeticholic acid in Italian patients with primary biliary cholangitis. Digestive and Liver Disease, 2018, 50, 26.	0.9	0
139	Female preponderance of primary biliary cholangitis is all about our understanding of its autoimmune nature. Hepatology, 2018, 67, 1210-1212.	7.3	3
140	Dermatological Complications After Solid Organ Transplantation. Clinical Reviews in Allergy and Immunology, 2018, 54, 185-212.	6.5	42
141	Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome. American Journal of Gastroenterology, 2018, 113, 254-264.	0.4	64
142	Milder disease stage in patients with primary biliary cholangitis over a 44â€year period: A changing natural history. Hepatology, 2018, 67, 1920-1930.	7.3	55
143	A functional characteristic of cysteineâ€rich protein 61: Modulation of myeloidâ€derived suppressor cells in liver inflammation. Hepatology, 2018, 67, 232-246.	7.3	39
144	Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. Gut, 2018, 67, 1517-1524.	12.1	42

#	Article	IF	CITATIONS
145	Primary Biliary Cholangitis (PBC): The emotional perception of the disease journey from a patient's perspective. Digestive and Liver Disease, 2018, 50, 57.	0.9	0
146	Prognostic models in primary biliary cholangitis. Journal of Autoimmunity, 2018, 95, 171-178.	6.5	22
147	"l Miss My Liver.―Nonmedical Sources in the History of Hepatocentrism. Hepatology Communications, 2018, 2, 986-993.	4.3	11
148	The immunobiology of female predominance in primary biliary cholangitis. Journal of Autoimmunity, 2018, 95, 124-132.	6.5	24
149	Ursodeoxycholic acid treatment is associated with prolonged transplant-free survival in primary biliary cholangitis – even in patients without biochemical improvements. Journal of Hepatology, 2018, 68, S8.	3.7	7
150	Geoepidemiology and (epi-)genetics in primary biliary cholangitis. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2018, 34-35, 11-15.	2.4	8
151	Individualizing Care. Clinics in Liver Disease, 2018, 22, 545-561.	2.1	3
152	The Epigenetics of Primary Biliary Cholangitis. , 2018, , 251-272.		0
153	Younger age is associated with lower transplant-free survival relative to a general population in patients with Primary Biliary Cholangitis. Journal of Hepatology, 2018, 68, S222-S223.	3.7	0
154	Stratification of hepatocellular carcinoma risk using the GLOBE score in patients with primary biliary cholangitis– the Global PBC Study Group. Journal of Hepatology, 2018, 68, S229-S230.	3.7	0
155	Support of precision medicine through risk-stratification in autoimmune liver diseases – histology, scoring systems, and non-invasive markers. Autoimmunity Reviews, 2018, 17, 854-865.	5.8	29
156	Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score. The Lancet Gastroenterology and Hepatology, 2018, 3, 626-634.	8.1	103
157	A dose-response relationship in the association between ursodeoxycholic acid treatment and prolonged transplant-free survival in primary biliary cholangitis. Journal of Hepatology, 2018, 68, S230.	3.7	Ο
158	Ursodeoxycholate inhibits mast cell activation and reverses biliary injury and fibrosis in Mdr2â^'/â^' mice and human primary sclerosing cholangitis. Laboratory Investigation, 2018, 98, 1465-1477.	3.7	29
159	Study of the influence of heme oxygenase 1 gene single nucleotide polymorphism (rs2071746) on esophageal varices among patients with cirrhosis. European Journal of Gastroenterology and Hepatology, 2018, 30, 888-892.	1.6	8
160	The fingerprint of antimitochondrial antibodies and the etiology of primary biliary cholangitis. Hepatology, 2017, 65, 1670-1682.	7.3	33
161	miR-24 Inhibition Increases Menin Expression and Decreases Cholangiocarcinoma Proliferation. American Journal of Pathology, 2017, 187, 570-580.	3.8	29
162	Primary Biliary Cholangitis Associated with Skin Disorders: A Case Report and Review of the Literature. Archivum Immunologiae Et Therapiae Experimentalis, 2017, 65, 299-309.	2.3	14

#	Article	IF	CITATIONS
163	Enhanced liver fibrosis test predicts transplantâ€free survival in primary sclerosing cholangitis, a multiâ€centre study. Liver International, 2017, 37, 1554-1561.	3.9	54
164	Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. Gastroenterology, 2017, 152, 1975-1984.e8.	1.3	355
165	Substance P increases liver fibrosis by differential changes in senescence of cholangiocytes and hepatic stellate cells. Hepatology, 2017, 66, 528-541.	7.3	67
166	EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. Journal of Hepatology, 2017, 67, 145-172.	3.7	889
167	Knockdown of Hepatic Gonadotropin-Releasing Hormone by Vivo-Morpholino Decreases Liver Fibrosis in Multidrug Resistance Gene 2 Knockout Mice by Down-Regulation of miR-200b. American Journal of Pathology, 2017, 187, 1551-1565.	3.8	14
168	Primary Biliary Cholangitis: advances in management and treatment of the disease. Digestive and Liver Disease, 2017, 49, 841-846.	0.9	23
169	Inhibition of the apelin/apelin receptor axis decreases cholangiocarcinoma growth. Cancer Letters, 2017, 386, 179-188.	7.2	41
170	Prolonged darkness reduces liver fibrosis in a mouse model of primary sclerosing cholangitis by miRâ€200b downâ€regulation. FASEB Journal, 2017, 31, 4305-4324.	0.5	45
171	Durable response in the markers of cholestasis through 24 months of open-label extension with obeticholic acid in Italian patients with primary biliary cholangitis. Digestive and Liver Disease, 2017, 49, e21.	0.9	0
172	Treatment of <scp>PBC</scp> —A step forward. Liver International, 2017, 37, 503-505.	3.9	4
173	Human β-Defensin 2 in Primary Sclerosing Cholangitis. Clinical and Translational Gastroenterology, 2017, 8, e80.	2.5	3
174	Nicotine Promotes Cholangiocarcinoma Growth in Xenograft Mice. American Journal of Pathology, 2017, 187, 1093-1105.	3.8	17
175	Expert clinical management of autoimmune hepatitis in the real world. Alimentary Pharmacology and Therapeutics, 2017, 45, 723-732.	3.7	66
176	Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. Nature Genetics, 2017, 49, 269-273.	21.4	230
177	Skin Manifestations Associated with Autoimmune Liver Diseases: a Systematic Review. Clinical Reviews in Allergy and Immunology, 2017, 53, 394-412.	6.5	27
178	From pathogenesis to novel therapies in the treatment of primary biliary cholangitis. Expert Review of Clinical Immunology, 2017, 13, 1121-1131.	3.0	12
179	Secretin-Stimulation of Bicarbonate Secretion Reduces Biliary Damage and Liver Fibrosis in a Model of Primary Biliary Cholangitis (PBC). Gastroenterology, 2017, 152, S1060.	1.3	1
180	Dysregulation of Iron Metabolism in Cholangiocarcinoma Stem-like Cells. Scientific Reports, 2017, 7, 17667.	3.3	60

#	Article	IF	CITATIONS
181	Inhibition of microRNA-24 increases liver fibrosis by enhanced menin expression in Mdr2 â^/lâ^' mice. Journal of Surgical Research, 2017, 217, 160-169.	1.6	15
182	Forkhead box A2 regulates biliary heterogeneity and senescence during cholestatic liver injury in mice‡. Hepatology, 2017, 65, 544-559.	7.3	43
183	Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated macrophages. Journal of Hepatology, 2017, 66, 102-115.	3.7	130
184	Cytokines in the Liver. , 2017, , 75-96.		2
185	Novel therapeutics for primary biliary cholangitis: Toward a disease-stage-based approach. Autoimmunity Reviews, 2016, 15, 870-876.	5.8	32
186	The epigenetics of PBC: The link between genetic susceptibility and environment. Clinics and Research in Hepatology and Gastroenterology, 2016, 40, 650-659.	1.5	26
187	The secretin/secretin receptor axis modulates liver fibrosis through changes in transforming growth factorâ€Î²1 biliary secretion in mice. Hepatology, 2016, 64, 865-879.	7.3	79
188	Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. Clinical and Experimental Immunology, 2016, 185, 61-71.	2.6	75
189	Evolving Trends in Female to Male Incidence and Male Mortality of Primary Biliary Cholangitis. Scientific Reports, 2016, 6, 25906.	3.3	132
190	Sa1567 UDCA Treatment Reverses Biliary Proliferation and Hepatic Fibrosis in Mdr2â^'/â^'Mice and Human PSC By Decreasing Mast Cell Infiltration and Histamine Release. Gastroenterology, 2016, 150, S1069.	1.3	0
191	Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nature Reviews Gastroenterology and Hepatology, 2016, 13, 261-280.	17.8	964
192	Sa1579 Durable Response in the Markers of Cholestasis through 18 Months of Open-Label Long Term Safety Extension Study of Obeticholic Acid in Primary Biliary Cirrhosis. Gastroenterology, 2016, 150, S1073-S1074.	1.3	1
193	A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. New England Journal of Medicine, 2016, 375, 631-643.	27.0	817
194	Effects of Acute Carnosine and β-Alanine on Isometric Force and Jumping Performance. International Journal of Sports Physiology and Performance, 2016, 11, 344-349.	2.3	4
195	Inhibition of mast cellâ€secreted histamine decreases biliary proliferation and fibrosis in primary sclerosing cholangitis Mdr2â^'/â^' mice. Hepatology, 2016, 64, 1202-1216.	7.3	63
196	Knockout of microRNA-21 reduces biliary hyperplasia and liver fibrosis in cholestatic bile duct ligated mice. Laboratory Investigation, 2016, 96, 1256-1267.	3.7	47
197	Novel treatments targeting immuneâ€related mechanisms in primary biliary cholangitis. Clinical Liver Disease, 2016, 8, 127-131.	2.1	1
198	Identification of Circulating MicroRNAs in Biliary Atresia by Nextâ€Generation Sequencing. Journal of Pediatric Gastroenterology and Nutrition, 2016, 63, 518-523.	1.8	23

#	Article	IF	CITATIONS
199	Toward precision medicine in primary biliary cholangitis. Digestive and Liver Disease, 2016, 48, 843-850.	0.9	12
200	Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. Gut, 2016, 65, 321-329.	12.1	139
201	Elevated circulating CD14lowCD16+ monocyte subset in primary biliary cirrhosis correlates with liver injury and promotes Th1 polarization. Clinical and Experimental Medicine, 2016, 16, 511-521.	3.6	19
202	Lack of Siglec-7 expression identifies a dysfunctional natural killer cell subset associated with liver inflammation and fibrosis in chronic HCV infection. Gut, 2016, 65, 1998-2006.	12.1	50
203	AISF position paper on liver disease and pregnancy. Digestive and Liver Disease, 2016, 48, 120-137.	0.9	32
204	Serum antinuclear and extractable nuclear antigen antibody prevalence and associated morbidity and mortality in the general population over 15years. Autoimmunity Reviews, 2016, 15, 162-166.	5.8	44
205	Making Sense of Autoantibodies in Cholestatic Liver Diseases. Clinics in Liver Disease, 2016, 20, 33-46.	2.1	22
206	Human liver-resident CD56bright/CD16neg NK cells are retained within hepatic sinusoids via the engagement of CCR5 and CXCR6 pathways. Journal of Autoimmunity, 2016, 66, 40-50.	6.5	220
207	Cancer stem cells and tumor-associated macrophages: a roadmap for multitargeting strategies. Oncogene, 2016, 35, 671-682.	5.9	122
208	Quantitation of the Rank-Rankl Axis in Primary Biliary Cholangitis. PLoS ONE, 2016, 11, e0159612.	2.5	23
209	The "gut microbiota―hypothesis in primary sclerosing cholangitis. Annals of Translational Medicine, 2016, 4, 512-512.	1.7	10
210	Changing nomenclature for PBC: From †̃cirrhosis' to †̃cholangitis'. Hepatology, 2015, 62, 1620-1622.	7.3	125
211	Therapeutic Potential of IL-17-Mediated Signaling Pathway in Autoimmune Liver Diseases. Mediators of Inflammation, 2015, 2015, 1-12.	3.0	22
212	Changing nomenclature for PBC: From †̃cirrhosis' to †̃cholangitis'. Clinics and Research in Hepatology and Gastroenterology, 2015, 39, e57-e59.	1.5	36
213	Geoepidemiology, Genetic and Environmental Risk Factors for PBC. Digestive Diseases, 2015, 33, 94-101.	1.9	32
214	Advances in pharmacotherapy for primary biliary cirrhosis. Expert Opinion on Pharmacotherapy, 2015, 16, 633-643.	1.8	31
215	Infection and Autoimmune Liver Diseases. , 2015, , 839-857.		0
216	The cumulative effects of known susceptibility variants to predict primary biliary cirrhosis risk. Genes and Immunity, 2015, 16, 193-198.	4.1	17

#	Article	IF	CITATIONS
217	Impact of microenvironment and stem-like plasticity in cholangiocarcinoma: Molecular networks and biological concepts. Journal of Hepatology, 2015, 62, 198-207.	3.7	66
218	P1147 : Validation of an alkaline phosphatase and bilirubin response criterion as biomarker for transplant-free survival in primary biliary cirrhosis in the world's two largest cohorts. Journal of Hepatology, 2015, 62, S782-S783.	3.7	0
219	Peak inflammation in atherosclerosis, primary biliary cirrhosis and autoimmune arthritis is counter-intuitively associated with regulatory T cell enrichment. Immunobiology, 2015, 220, 1025-1029.	1.9	20
220	The overlap syndrome between primary biliary cirrhosis and primary sclerosing cholangitis. Digestive and Liver Disease, 2015, 47, 432-435.	0.9	26
221	Changing Nomenclature for PBC: From â€~Cirrhosis' to â€~Cholangitis'. American Journal of Gastroenterology, 2015, 110, 1536-1538.	0.4	30
222	Changing nomenclature for PBC: From â€~cirrhosis' to â€~cholangitis'. Digestive and Liver Disease, 2015, 924-926.	47. 0.9	15
223	Changing Nomenclature for PBC: From â€~Cirrhosis' to â€~Cholangitis'. Gastroenterology, 2015, 149, 1627-1629.	1.3	96
224	Changing Nomenclature for PBC: From â€~Cirrhosis' to â€~Cholangitis'. Clinical Gastroenterology and Hepatology, 2015, 13, 1867-1869.	4.4	16
225	International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways. Nature Communications, 2015, 6, 8019.	12.8	245
226	Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. Gastroenterology, 2015, 149, 1804-1812.e4.	1.3	330
227	Changing nomenclature for PBC: From †̃cirrhosis' to †̃cholangitis'. Journal of Hepatology, 2015, 63, 1285-1287.	3.7	85
228	Interpretation and Perception of Two Different Kumite Fighting Intensities through an Integrated Approach Training in International Level Karatekas: An Exploratory Study. Perceptual and Motor Skills, 2015, 121, 333-349.	1.3	5
229	DNA methylation profiling of the X chromosome reveals an aberrant demethylation on CXCR3 promoter in primary biliary cirrhosis. Clinical Epigenetics, 2015, 7, 61.	4.1	83
230	Changing nomenclature for PBC: from †̃cirrhosis' to †̃cholangitis'. Gut, 2015, 64, 1671-1672.	12.1	28
231	Autonomic modulations of heart rate variability and performances in short-distance elite swimmers. European Journal of Applied Physiology, 2015, 115, 825-835.	2.5	16
232	OC-030â€Effective Stratification Of Hepatocellular Carcinoma Risk In Primary Biliary Cirrhosis: Results Of A Multi-centre International Study. Gut, 2014, 63, A15-A16.	12.1	0
233	Genetics and Epigenetics of Primary Biliary Cirrhosis. Seminars in Liver Disease, 2014, 34, 255-264.	3.6	42
234	Interpretation and Perception of Slow, Moderate, and Fast Swimming Paces in Distance and Sprint Swimmers. Perceptual and Motor Skills, 2014, 118, 833-849.	1.3	7

#	Article	IF	CITATIONS
235	Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up Study. Gastroenterology, 2014, 147, 1338-1349.e5.	1.3	365
236	Nuclear Envelope Protein Autoantibodies/Antilamin Autoantibodies. , 2014, , 219-223.		0
237	Primary Biliary Cirrhosis. Seminars in Liver Disease, 2014, 34, 253-254.	3.6	6
238	Genome-Wide Analysis of DNA Methylation, Copy Number Variation, and Gene Expression in Monozygotic Twins Discordant for Primary Biliary Cirrhosis. Frontiers in Immunology, 2014, 5, 128.	4.8	57
239	Gene dosage as a relevant mechanism contributing to the determination of ovarian function in Turner syndrome. Human Reproduction, 2014, 29, 368-379.	0.9	39
240	Telomere dysfunction in peripheral blood mononuclear cells from patients with primary biliary cirrhosis. Digestive and Liver Disease, 2014, 46, 363-368.	0.9	11
241	Macrophage plasticity and polarization in liver homeostasis and pathology. Hepatology, 2014, 59, 2034-2042.	7.3	359
242	Implications of genomeâ€wide association studies in novel therapeutics in primary biliary cirrhosis. European Journal of Immunology, 2014, 44, 945-954.	2.9	34
243	Smooth Muscle Autoantibodies. , 2014, , 491-495.		Ο
244	New therapeutics in primary biliary cirrhosis: will there ever be light?. Liver International, 2014, 34, 167-170.	3.9	8
245	Shotgun proteomics: Identification of unique protein profiles of apoptotic bodies from biliary epithelial cells. Hepatology, 2014, 60, 1314-1323.	7.3	68
246	Stem cell niche and macrophages in human cholangiocarcinoma. Digestive and Liver Disease, 2014, 46, e4.	0.9	0
247	Secretin Stimulates Biliary Cell Proliferation by Regulating Expression of MicroRNA 125b and MicroRNA let7a in Mice. Gastroenterology, 2014, 146, 1795-1808.e12.	1.3	83
248	The critical role of myeloid-derived suppressor cells and FXR activation in immune-mediated liver injury. Journal of Autoimmunity, 2014, 53, 55-66.	6.5	34
249	Vitamin D in autoimmune liver disease. Clinics and Research in Hepatology and Gastroenterology, 2013, 37, 535-545.	1.5	45
250	Tracing environmental markers of autoimmunity: introducing the infectome. Immunologic Research, 2013, 56, 220-240.	2.9	35
251	Apotopes and innate immune system: Novel players in the primary biliary cirrhosis scenario. Digestive and Liver Disease, 2013, 45, 630-636.	0.9	24
252	Intrahepatic cholestasis of pregnancy: A further important step in dissecting its genetic architecture. Digestive and Liver Disease, 2013, 45, 266-267.	0.9	5

#	Article	IF	CITATIONS
253	Infectome: A platform to trace infectious triggers of autoimmunity. Autoimmunity Reviews, 2013, 12, 726-740.	5.8	94
254	Liver auto-immunology: The paradox of autoimmunity in a tolerogenic organ. Journal of Autoimmunity, 2013, 46, 1-6.	6.5	44
255	The limitations and hidden gems of the epidemiology of primary biliary cirrhosis. Journal of Autoimmunity, 2013, 46, 81-87.	6.5	64
256	Y chromosome loss in male patients with primary biliary cirrhosis. Journal of Autoimmunity, 2013, 41, 87-91.	6.5	93
257	941 ALKALINE PHOSPHATASE VALUES ARE A SURROGATE MARKER IN PREDICTION OF TRANSPLANT FREE SURVIVAL IN PATIENTS WITH PRIMARY BILIARY CIRRHOSIS – AN INTERNATIONAL, COLLABORATIVE ANALYSIS. Journal of Hepatology, 2013, 58, S388.	3.7	0
258	Methylation and liver cancer. Clinics and Research in Hepatology and Gastroenterology, 2013, 37, 564-571.	1.5	15
259	Overexpression of microRNA-21 is associated with elevated pro-inflammatory cytokines in dominant-negative TGF-1² receptor type II mouse. Journal of Autoimmunity, 2013, 41, 111-119.	6.5	95
260	Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nature Genetics, 2013, 45, 670-675.	21.4	339
261	Pathway-based analysis of primary biliary cirrhosis genome-wide association studies. Genes and Immunity, 2013, 14, 179-186.	4.1	52
262	Identification of serum and tissue micro-RNA expression profiles in different stages of inflammatory bowel disease. Clinical and Experimental Immunology, 2013, 173, 250-258.	2.6	109
263	Serum Autoantibodies: From Identification to Clinical Relevance. Clinical and Developmental Immunology, 2013, 2013, 1-3.	3.3	2
264	Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. Human Molecular Genetics, 2012, 21, 5209-5221.	2.9	139
265	Identification of New Autoantigens by Protein Array Indicates a Role for IL4 Neutralization in Autoimmune Hepatitis. Molecular and Cellular Proteomics, 2012, 11, 1885-1897.	3.8	38
266	Sex Differences Associated with Primary Biliary Cirrhosis. Clinical and Developmental Immunology, 2012, 2012, 1-11.	3.3	37
267	Interleukin-6-driven progranulin expression increases cholangiocarcinoma growth by an Akt-dependent mechanism. Gut, 2012, 61, 268-277.	12.1	101
268	Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis. Genes and Immunity, 2012, 13, 461-468.	4.1	75
269	Iron levels in polarized macrophages: Regulation of immunity and autoimmunity. Autoimmunity Reviews, 2012, 11, 883-889.	5.8	109
270	Th17 and regulatory T lymphocytes in primary biliary cirrhosis and systemic sclerosis as models of autoimmune fibrotic diseases. Autoimmunity Reviews, 2012, 12, 300-304.	5.8	70

#	Article	IF	CITATIONS
271	Towards systemic sclerosis and away from primary biliary cirrhosis: the case of PTPN22. Autoimmunity Highlights, 2012, 3, 1-9.	3.9	8
272	The X-factor in primary biliary cirrhosis: monosomy X and xenobiotics. Autoimmunity Highlights, 2012, 3, 127-132.	3.9	4
273	Towards common denominators in primary biliary cirrhosis: The role of IL-12. Journal of Hepatology, 2012, 56, 731-733.	3.7	38
274	Role of the stromal-derived factor-1 (SDF-1)–CXCR4 axis in the interaction between hepatic stellate cells and cholangiocarcinoma. Journal of Hepatology, 2012, 57, 813-820.	3.7	82
275	Increased loss of the Y chromosome in peripheral blood cells in male patients with autoimmune thyroiditis. Journal of Autoimmunity, 2012, 38, J193-J196.	6.5	64
276	The X chromosome and immune associated genes. Journal of Autoimmunity, 2012, 38, J187-J192.	6.5	277
277	Autoimmune hepatitis type 2 associated with an unexpected and transient presence of primary biliary cirrhosis-specific antimitochondrial antibodies: a case study and review of the literature. BMC Gastroenterology, 2012, 12, 92.	2.0	24
278	Comparative analysis of portal cell infiltrates in antimitochondrial autoantibody-positive versus antimitochondrial autoantibody-negative primary biliary cirrhosis. Hepatology, 2012, 55, 1495-1506.	7.3	35
279	Overcoming a "Probable―Diagnosis in Antimitochondrial Antibody Negative Primary Biliary Cirrhosis: Study of 100 Sera and Review of the Literature. Clinical Reviews in Allergy and Immunology, 2012, 42, 288-297.	6.5	70
280	MicroRNAs in autoimmunity and inflammatory bowel disease: Crucial regulators in immune response. Autoimmunity Reviews, 2012, 11, 305-314.	5.8	150
281	Autoimmunity and Turner's syndrome. Autoimmunity Reviews, 2012, 11, A538-A543.	5.8	73
282	Immunoglobulin M levels inversely correlate with CD40 ligand promoter methylation in patients with primary biliary cirrhosis. Hepatology, 2012, 55, 153-160.	7.3	116
283	Primary Biliary Cirrhosis: Bad Genes, Bad Luck. Digestive Diseases and Sciences, 2012, 57, 599-601.	2.3	6
284	Identification of Serum and Tissue Micro-RNA Expression Profiles in Different Stages of the Inflammatory Bowel Disease. Gastroenterology, 2011, 140, S-273.	1.3	0
285	Cholangiocarcinoma in Italy: A national survey on clinical characteristics, diagnostic modalities and treatment. Results from the "Cholangiocarcinoma―committee of the Italian Association for the Study of Liver disease. Digestive and Liver Disease, 2011, 43, 60-65.	0.9	59
286	Primary sclerosing cholangitis is changing clinical spectrum and old biomarkers disclose an innovative role: The case of alkaline phosphatase. Digestive and Liver Disease, 2011, 43, 268-269.	0.9	1
287	Melatonin Inhibits In Vivo Cholangiocarcinoma Growth by Enhanced Biliary Expression of Serotonin N-Acetyltransferase (AANAT) the Key Enzyme Involved in Melatonin Synthesis. Gastroenterology, 2011, 140, S-910.	1.3	0
288	Genetic association of <i>Fc receptorâ€like 3</i> polymorphisms with susceptibility to primary biliary cirrhosis: ethnic comparative study in Japanese and Italian patients. Tissue Antigens, 2011, 77, 239-243.	1.0	21

#	Article	IF	CITATIONS
289	Replicated association of 17q12â€21 with susceptibility of primary biliary cirrhosis in a Japanese cohort. Tissue Antigens, 2011, 78, 65-68.	1.0	31
290	Immunopathogenesis of primary biliary cirrhosis: an old wives' tale. Immunity and Ageing, 2011, 8, 12.	4.2	25
291	Epithelial cell specificity and apotope recognition by serum autoantibodies in primary biliary cirrhosis. Hepatology, 2011, 54, 196-203.	7.3	60
292	Human leukocyte antigen in primary biliary cirrhosis: An old story now reviving. Hepatology, 2011, 54, 714-723.	7.3	74
293	Epigenetic investigation of variably X chromosome inactivated genes in monozygotic female twins discordant for primary biliary cirrhosis. Epigenetics, 2011, 6, 95-102.	2.7	74
294	Progress in the Genetics of Primary Biliary Cirrhosis. Seminars in Liver Disease, 2011, 31, 147-156.	3.6	66
295	†It's as if PBC didn't exist': The illness experience of women affected by primary biliary cirrhosis. Psychology and Health, 2011, 26, 1429-1445.	2.2	18
296	Melatonin exerts by an autocrine loop antiproliferative effects in cholangiocarcinoma; its synthesis is reduced favoring cholangiocarcinoma growth. American Journal of Physiology - Renal Physiology, 2011, 301, G623-G633.	3.4	46
297	Hunting for fibrosis progression genes in hepatitis C patients. Clinical Science, 2011, 120, 285-286.	4.3	0
298	Neuropeptide Y inhibits cholangiocarcinoma cell growth and invasion. American Journal of Physiology - Cell Physiology, 2011, 300, C1078-C1089.	4.6	27
299	Increased local dopamine secretion has growthâ€promoting effects in cholangiocarcinoma. International Journal of Cancer, 2010, 126, 2112-2122.	5.1	46
300	Definition of human autoimmunity — autoantibodies versus autoimmune disease. Autoimmunity Reviews, 2010, 9, A259-A266.	5.8	210
301	Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis. Hepatology, 2010, 52, 987-998.	7.3	194
302	Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver. Hepatology, 2010, 52, 1758-1768.	7.3	36
303	Prevalence of primary biliary cirrhosis in adults referring hospital for annual health check-up in Southern China. BMC Gastroenterology, 2010, 10, 100.	2.0	67
304	Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nature Genetics, 2010, 42, 658-660.	21.4	389
305	Experimental evidence on the immunopathogenesis of primary biliary cirrhosis. Cellular and Molecular Immunology, 2010, 7, 1-10.	10.5	47
306	A short version of a HRQoL questionnaire for Italian and Japanese patients with Primary Biliary Cirrhosis. Digestive and Liver Disease, 2010, 42, 718-723.	0.9	26

#	Article	IF	CITATIONS
307	Update on primary biliary cirrhosis. Digestive and Liver Disease, 2010, 42, 401-408.	0.9	65
308	Genetic associations in Italian primary sclerosing cholangitis: Heterogeneity across Europe defines a critical role for HLA-C. Journal of Hepatology, 2010, 52, 712-717.	3.7	50
309	Drug-induced liver injury: Is it time for genetics to change our clinical practice?. Journal of Hepatology, 2010, 53, 993-994.	3.7	7
310	A comprehensive evaluation of serum autoantibodies in primary biliary cirrhosis. Journal of Autoimmunity, 2010, 34, 55-58.	6.5	92
311	Geoepidemiology of autoimmune liver diseases. Journal of Autoimmunity, 2010, 34, J300-J306.	6.5	83
312	Phenotypical and functional alterations of CD8 regulatory T cells in primary biliary cirrhosis. Journal of Autoimmunity, 2010, 35, 176-180.	6.5	64
313	PBC Screen: An IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. Journal of Autoimmunity, 2010, 35, 436-442.	6.5	123
314	Immune-mediated bile duct injury: The case of primary biliary cirrhosis. World Journal of Gastrointestinal Pathophysiology, 2010, 1, 118.	1.0	5
315	TNFâ€Î± Polymorphisms in Primary Biliary Cirrhosis: A Northern and Southern Italian Experience. Annals of the New York Academy of Sciences, 2009, 1173, 557-563.	3.8	12
316	Effect of <scp>L</scp> -Acetylcarnitine on Body Composition in HIV-related Lipodystrophy. Hormone and Metabolic Research, 2009, 41, 840-845.	1.5	23
317	Apotopes and the biliary specificity of primary biliary cirrhosis. Hepatology, 2009, 49, 871-879.	7.3	193
318	Keratin variants are overrepresented in primary biliary cirrhosis and associate with disease severity. Hepatology, 2009, 50, 546-554.	7.3	44
319	Future directions in genetic for autoimmune diseases. Journal of Autoimmunity, 2009, 33, 1-2.	6.5	48
320	Female predominance and X chromosome defects in autoimmune diseases. Journal of Autoimmunity, 2009, 33, 12-16.	6.5	158
321	The genetics of human autoimmune disease. Journal of Autoimmunity, 2009, 33, 290-299.	6.5	78
322	Vitamin D receptor polymorphisms are associated with increased susceptibility to primary biliary cirrhosis in Japanese and Italian populations. Journal of Hepatology, 2009, 50, 1202-1209.	3.7	85
323	EASL Clinical Practice Guidelines: Management of cholestatic liver diseases. Journal of Hepatology, 2009, 51, 237-267.	3.7	1,540
324	Acute liver and renal failure during treatment with buprenorphine at therapeutic dose. Digestive and Liver Disease, 2009, 41, e8-e10.	0.9	38

#	Article	IF	CITATIONS
325	Human cholangiocarcinoma development is associated with dysregulation of opioidergic modulation of cholangiocyte growth. Digestive and Liver Disease, 2009, 41, 523-533.	0.9	12
326	Validation of the Japanese version of the Fisk Fatigue Severity Score (FFSS) in Japanese patients with primary biliary cirrhosis. Acta Hepatologica Japonica, 2009, 50, 51-59.	0.1	1
327	Characterization of the antibodies to p62 nucleoporin in primary biliary cirrhosis using human recombinant antigen. Journal of Cellular Biochemistry, 2008, 104, 27-37.	2.6	13
328	Human leukocyte antigen polymorphisms in italian primary biliary cirrhosis: A multicenter study of 664 patients and 1992 healthy controls. Hepatology, 2008, 48, 1906-1912.	7.3	120
329	The Genetic Basis of Primary Biliary Cirrhosis: Premises, Not Promises. Gastroenterology, 2008, 135, 1044-1047.	1.3	21
330	Skewing of X chromosome inactivation in autoimmunity. Autoimmunity, 2008, 41, 272-277.	2.6	41
331	New functions for an iron storage protein: The role of ferritin in immunity and autoimmunity. Journal of Autoimmunity, 2008, 30, 84-89.	6.5	222
332	The consequences of apoptosis in autoimmunity. Journal of Autoimmunity, 2008, 31, 257-262.	6.5	122
333	Impaired indoleamine 2,3-dioxygenase production contributes to the development of autoimmunity in primary biliary cirrhosis. Autoimmunity, 2008, 41, 92-99.	2.6	13
334	Serotonin Metabolism Is Dysregulated in Cholangiocarcinoma, which Has Implications for Tumor Growth. Cancer Research, 2008, 68, 9184-9193.	0.9	90
335	Serum autoantibodies: A road map for the clinical hepatologist. Autoimmunity, 2008, 41, 27-34.	2.6	23
336	X chromosome in autoimmune diseases. Expert Review of Clinical Immunology, 2008, 4, 591-597.	3.0	4
337	Autoimmune liver diseases. World Journal of Gastroenterology, 2008, 14, 3290.	3.3	26
338	Clinical features and management of primary biliary cirrhosis. World Journal of Gastroenterology, 2008, 14, 3313.	3.3	41
339	Etiopathogenesis of primary biliary cirrhosis. World Journal of Gastroenterology, 2008, 14, 3328.	3.3	80
340	Autoimmune liver serology: Current diagnostic and clinical challenges. World Journal of Gastroenterology, 2008, 14, 3374.	3.3	185
341	WHAT IS AN AUTOANTIBODY?. , 2007, , 3-6.		1
342	Interpreting Serological Tests in Diagnosing Autoimmune Liver Diseases. Seminars in Liver Disease, 2007, 27, 161-172.	3.6	100

#	Article	IF	CITATIONS
343	Cytokines in Liver Health and Disease. , 2007, , 83-93.		2
344	NUCLEAR ENVELOPE PROTEIN AUTOANTIBODIES/ANTILAMIN AUTOANTIBODIES. , 2007, , 191-196.		1
345	Serum and Biliary Insulin-like Growth Factor I and Vascular Endothelial Growth Factor in Determining the Cause of Obstructive Cholestasis. Annals of Internal Medicine, 2007, 147, 451.	3.9	52
346	Autophagy: Highlighting a novel player in the autoimmunity scenario. Journal of Autoimmunity, 2007, 29, 61-68.	6.5	91
347	ANTINUCLEAR ANTIBODIES: GENERAL INTRODUCTION. , 2007, , 129-133.		3
348	ANTIMITOCHONDRIAL ANTIBODIES., 2007, , 473-477.		2
349	Biliary insulin like growth factor-1 (IGF1) is a sensitive marker for the diagnosis of extrahepatic cholangiocarcinoma. Digestive and Liver Disease, 2007, 39, A5.	0.9	0
350	A sensitive bead assay for antimitochondrial antibodies: Chipping away at AMA-negative primary biliary cirrhosis. Hepatology, 2007, 45, 659-665.	7.3	152
351	Preferential X chromosome loss but random inactivation characterize primary biliary cirrhosis. Hepatology, 2007, 46, 456-462.	7.3	124
352	Quality of life and everyday activities in patients with primary biliary cirrhosis. Hepatology, 2007, 46, 1836-1843.	7.3	30
353	Role of X chromosome defects in primary biliary cirrhosis. Hepatology Research, 2007, 37, S384-S388.	3.4	4
354	Characterization of Autoantibodies against Components of the Nuclear Pore Complexes: High Frequency of Anti-p62 Nucleoporin Antibodies. Annals of the New York Academy of Sciences, 2007, 1109, 519-530.	3.8	23
355	The X Chromosome in Female-Predominant Autoimmune Diseases. Annals of the New York Academy of Sciences, 2007, 1110, 57-64.	3.8	30
356	X Monosomy in Female Systemic Lupus Erythematosus. Annals of the New York Academy of Sciences, 2007, 1110, 84-91.	3.8	48
357	Bovine fetal microchimerism in normal and embryo transfer pregnancies and its implications for biotechnology applications in cattle. Biotechnology Journal, 2007, 2, 486-491.	3.5	27
358	Fetal Microchimerism in Normal and Embryo Transfer Bovine Pregnancies. Veterinary Research Communications, 2007, 31, 205-207.	1.6	12
359	Primary Biliary Cirrhosis and Autoimmune Cholangitis. , 2007, , 235-247.		1

Autoantibody Recognition of Functional Sites. , 2006, , 473-491.

0

#	Article	IF	CITATIONS
361	The X chromosome and systemic sclerosis. Current Opinion in Rheumatology, 2006, 18, 601-605.	4.3	24
362	Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology, 2006, 43, 1135-1144.	7.3	171
363	Primary Biliary Cirrhosis: Solving the Enigma. Annals of the New York Academy of Sciences, 2005, 1051, 185-193.	3.8	12
364	Soluble CD40L in Plasma of Patients with Primary Biliary Cirrhosis. Annals of the New York Academy of Sciences, 2005, 1051, 205-210.	3.8	5
365	Decreased Serum Leptin Levels in Primary Biliary Cirrhosis: A Link between Metabolism and Autoimmunity?. Annals of the New York Academy of Sciences, 2005, 1051, 211-217.	3.8	7
366	The Enigma of Primary Biliary Cirrhosis. Clinical Reviews in Allergy and Immunology, 2005, 28, 073-082.	6.5	16
367	Genes and (auto)immunity in primary biliary cirrhosis. Genes and Immunity, 2005, 6, 543-556.	4.1	35
368	Genes and goals: An approach to microarray analysis in autoimmunity. Autoimmunity Reviews, 2005, 4, 414-422.	5.8	28
369	Genetic polymorphisms influencing xenobiotic metabolism and transport in patients with primary biliary cirrhosis. Hepatology, 2005, 41, 55-63.	7.3	43
370	SNP Analysis of Genes Implicated in T Cell Proliferation in Primary Biliary Cirrhosis. Clinical and Developmental Immunology, 2005, 12, 259-263.	3.3	30
371	Lack of serum antibodies to membrane bound carbonic anhydrase IV in patients with primary biliary cirrhosis. Gut, 2005, 54, 1665-1665.	12.1	1
372	Genetics and Geoepidemiology of Primary Biliary Cirrhosis: Following the Footprints to Disease Etiology. Seminars in Liver Disease, 2005, 25, 265-280.	3.6	100
373	Antinuclear Antibodies in Primary Biliary Cirrhosis. Seminars in Liver Disease, 2005, 25, 298-310.	3.6	173
374	X Chromosome Monosomy: A Common Mechanism for Autoimmune Diseases. Journal of Immunology, 2005, 175, 575-578.	0.8	180
375	From Bases to Basis: Linking Genetics to Causation in Primary Biliary Cirrhosis. Clinical Gastroenterology and Hepatology, 2005, 3, 401-410.	4.4	79
376	Genetic polymorphisms of toll-like receptor 9 influence the immune response to CpG and contribute to hyper-IgM in primary biliary cirrhosis. Journal of Autoimmunity, 2005, 24, 347-352.	6.5	69
377	Antidiabetic thiazolidinediones induce ductal differentiation but not apoptosis in pancreatic cancer cells. World Journal of Gastroenterology, 2005, 11, 1122.	3.3	21
378	Antimitochondrial Antibodies and Reactivity to N. Aromaticivorans Proteins in Icelandic Patients with Primary Biliary Cirrhosis and Their Relatives. American Journal of Gastroenterology, 2004, 99, 2143-2146.	0.4	53

#	Article	IF	CITATIONS
379	Primary biliary cirrhosis: does X mark the spot?. Autoimmunity Reviews, 2004, 3, 493-499.	5.8	41
380	Tamoxifen in treatment of primary biliary cirrhosis. Hepatology, 2004, 39, 1175-1176.	7.3	23
381	Primary biliary cirrhosis in monozygotic and dizygotic twins: Genetics, epigenetics, and environment. Gastroenterology, 2004, 127, 485-492.	1.3	447
382	Lack of immunological or molecular evidence for a role of mouse mammary tumor retrovirus in primary biliary cirrhosis. Gastroenterology, 2004, 127, 493-501.	1.3	115
383	Estrogen receptors in cholangiocytes and the progression of primary biliary cirrhosis. Journal of Hepatology, 2004, 41, 905-912.	3.7	108
384	544 Prognostic value of autoantibodies against proteins of nuclear pore complexes (anti-NPCS) in early primary biliary cirrhosis (PBC). Journal of Hepatology, 2004, 40, 159-160.	3.7	27
385	Frequency of monosomy X in women with primary biliary cirrhosis. Lancet, The, 2004, 363, 533-535.	13.7	252
386	Epidemiology and Pathogenesis of Primary Biliary Cirrhosis. Journal of Clinical Gastroenterology, 2004, 38, 264-271.	2.2	65
387	Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. Hepatology, 2003, 38, 1250-1257.	7.3	281
388	Genetic variants of endothelial nitric oxide synthase in patients with primary biliary cirrhosis: Association with disease severity. Journal of Gastroenterology and Hepatology (Australia), 2003, 18, 1150-1155.	2.8	20
389	Peculiar HLA polymorphisms in Italian patients with primary biliary cirrhosis. Journal of Hepatology, 2003, 38, 401-406.	3.7	75
390	Effect of Anti-Carbonic Anhydrase Antibodies on Carbonic Anhydrases I and II. Clinical Chemistry, 2003, 49, 1221-1223.	3.2	33
391	Geographic Clusters of Primary Biliary Cirrhosis. Clinical and Developmental Immunology, 2003, 10, 127-131.	3.3	53
392	T-cell receptor polymorphism in primary biliary cirrhosis. Annali Italiani Di Medicina Interna: Organo Ufficiale Della Società Italiana Di Medicina Interna, 2003, 18, 149-53.	0.1	3
393	Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut, 2002, 51, 265-269.	12.1	150
394	The Search for a Practical Approach to Emerging Diseases: The Case of Severe Acute Respiratory Syndrome (SARS). Autoimmunity, 2002, 9, 113-117.	0.6	2
395	Presence of fetal DNA in maternal plasma decades after pregnancy. Human Genetics, 2002, 110, 587-591.	3.8	67
396	Presence of fetal DNA in maternal plasma decades after pregnancy: further comments. Human Genetics, 2002, 111, 576-576.	3.8	8

#	Article	IF	CITATIONS
397	Blood fetal microchimerism in primary biliary cirrhosis. Clinical and Experimental Immunology, 2001, 122, 418-422.	2.6	67
398	Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis. Journal of Hepatology, 2001, 34, 366-372.	3.7	150
399	Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double-blind, placebo-controlled trial on symptomatic patients. Alimentary Pharmacology and Therapeutics, 2001, 15, 1427-1434.	3.7	35
400	Hyperlipidemic state and cardiovascular risk in course of primary biliary cirrhosis. Gastroenterology, 2000, 118, A1008.	1.3	1
401	Conjugated bilirubin is an accurate marker of cholestasis in primary biliary cirrhosis. Gastroenterology, 2000, 118, A900.	1.3	0
402	Differences in the metabolism and disposition of ursodeoxycholic acid and of its taurine-conjugated species in patients with primary biliary cirrhosis. Hepatology, 1999, 29, 320-327.	7.3	75
403	Antibody to carbonic anhydrase II is present in primary biliary cirrhosis (PBC) irrespective of antimitochondrial antibody status. Clinical and Experimental Immunology, 1998, 114, 448-454.	2.6	55
404	Ursodeoxycholic and tauro-ursodeoxycholic acids for the treatment of primary biliary cirrhosis: a pilot crossover study. Alimentary Pharmacology and Therapeutics, 1997, 11, 409-414.	3.7	29
405	Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis. Hepatology, 1997, 25, 1090-1095.	7.3	286
406	Clinical Pharmacokinetics of Therapeutic Bile Acids. Clinical Pharmacokinetics, 1996, 30, 333-358.	3.5	79
407	Tauroursodeoxycholic acid for treatment of primary biliary cirrhosis. Digestive Diseases and Sciences, 1996, 41, 809-815.	2.3	43